ID   UBE2C_HUMAN             Reviewed;         179 AA.
AC   O00762; A6NP33; E1P5N7; G3XAB7;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 1.
DT   10-MAY-2017, entry version 176.
DE   RecName: Full=Ubiquitin-conjugating enzyme E2 C;
DE            EC=2.3.2.23 {ECO:0000269|PubMed:18485873, ECO:0000269|PubMed:20061386};
DE   AltName: Full=(E3-independent) E2 ubiquitin-conjugating enzyme C;
DE            EC=2.3.2.24 {ECO:0000269|PubMed:17588522};
DE   AltName: Full=E2 ubiquitin-conjugating enzyme C;
DE   AltName: Full=UbcH10;
DE   AltName: Full=Ubiquitin carrier protein C;
DE   AltName: Full=Ubiquitin-protein ligase C;
GN   Name=UBE2C; Synonyms=UBCH10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF CYS-114.
RX   PubMed=9122200; DOI=10.1073/pnas.94.6.2362;
RA   Townsley F.M., Aristarkhov A., Beck S., Hershko A., Ruderman J.V.;
RT   "Dominant-negative cyclin-selective ubiquitin carrier protein E2-
RT   C/UbcH10 blocks cells in metaphase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:2362-2367(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Lung adenocarcinoma, Lymph, Melanoma, Teratocarcinoma, and
RC   Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, UBIQUITINATION, AND MUTAGENESIS OF CYS-114.
RX   PubMed=15558010; DOI=10.1038/nature03023;
RA   Rape M., Kirschner M.W.;
RT   "Autonomous regulation of the anaphase-promoting complex couples
RT   mitosis to S-phase entry.";
RL   Nature 432:588-595(2004).
RN   [7]
RP   CATALYTIC ACTIVITY AS E3-INDEPENDENT E2 UBIQUITIN-CONJUGATING ENZYME.
RX   PubMed=17588522; DOI=10.1016/j.molcel.2007.05.014;
RA   Hoeller D., Hecker C.M., Wagner S., Rogov V., Doetsch V., Dikic I.;
RT   "E3-independent monoubiquitination of ubiquitin-binding proteins.";
RL   Mol. Cell 26:891-898(2007).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=18485873; DOI=10.1016/j.cell.2008.04.012;
RA   Jin L., Williamson A., Banerjee S., Philipp I., Rape M.;
RT   "Mechanism of ubiquitin-chain formation by the human anaphase-
RT   promoting complex.";
RL   Cell 133:653-665(2008).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   FUNCTION.
RX   PubMed=19820702; DOI=10.1038/ncb1983;
RA   Garnett M.J., Mansfeld J., Godwin C., Matsusaka T., Wu J., Russell P.,
RA   Pines J., Venkitaraman A.R.;
RT   "UBE2S elongates ubiquitin chains on APC/C substrates to promote
RT   mitotic exit.";
RL   Nat. Cell Biol. 11:1363-1369(2009).
RN   [11]
RP   FUNCTION.
RX   PubMed=19822757; DOI=10.1073/pnas.0907887106;
RA   Williamson A., Wickliffe K.E., Mellone B.G., Song L., Karpen G.H.,
RA   Rape M.;
RT   "Identification of a physiological E2 module for the human anaphase-
RT   promoting complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:18213-18218(2009).
RN   [12]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=20061386; DOI=10.1074/jbc.M109.089003;
RA   David Y., Ziv T., Admon A., Navon A.;
RT   "The E2 ubiquitin-conjugating enzymes direct polyubiquitination to
RT   preferred lysines.";
RL   J. Biol. Chem. 285:8595-8604(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-3, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS).
RX   PubMed=11927573; DOI=10.1074/jbc.M109398200;
RA   Lin Y., Hwang W.C., Basavappa R.;
RT   "Structural and functional analysis of the human mitotic-specific
RT   ubiquitin-conjugating enzyme, UbcH10.";
RL   J. Biol. Chem. 277:21913-21921(2002).
CC   -!- FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its
CC       covalent attachment to other proteins. In vitro catalyzes 'Lys-
CC       11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential
CC       factor of the anaphase promoting complex/cyclosome (APC/C), a cell
CC       cycle-regulated ubiquitin ligase that controls progression through
CC       mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains
CC       on APC/C substrates, leading to the degradation of APC/C
CC       substrates by the proteasome and promoting mitotic exit.
CC       {ECO:0000269|PubMed:15558010, ECO:0000269|PubMed:18485873,
CC       ECO:0000269|PubMed:19820702, ECO:0000269|PubMed:19822757,
CC       ECO:0000269|PubMed:20061386}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E1 ubiquitin-activating
CC       enzyme]-L-cysteine + [E2 ubiquitin-conjugating enzyme]-L-cysteine
CC       = [E1 ubiquitin-activating enzyme]-L-cysteine + S-ubiquitinyl-[E2
CC       ubiquitin-conjugating enzyme]-L-cysteine. {ECO:0000255|PROSITE-
CC       ProRule:PRU00388, ECO:0000255|PROSITE-ProRule:PRU10133,
CC       ECO:0000269|PubMed:18485873, ECO:0000269|PubMed:20061386}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E1 ubiquitin-activating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E1 ubiquitin-
CC       activating enzyme]-L-cysteine + N(6)-monoubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:17588522}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388,
CC       ECO:0000269|PubMed:18485873}.
CC   -!- SUBUNIT: Component of the APC/C complex.
CC       {ECO:0000269|PubMed:19820702}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O00762-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00762-2; Sequence=VSP_045647;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=O00762-3; Sequence=VSP_045648;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=O00762-4; Sequence=VSP_045649;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Autoubiquitinated by the APC/C complex, leading to its
CC       degradation by the proteasome. Its degradation plays a central
CC       role in APC/C regulation, allowing cyclin-A accumulation before S
CC       phase entry. APC/C substrates inhibit the autoubiquitination of
CC       UBE2C/UBCH10 but not its E2 function, hence APC/C remaining active
CC       until its substrates have been destroyed.
CC       {ECO:0000269|PubMed:15558010}.
CC   -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/UBE2CID44079ch20q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U73379; AAB53362.1; -; mRNA.
DR   EMBL; BT007300; AAP35964.1; -; mRNA.
DR   EMBL; AL050348; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75804.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75805.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75806.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75807.1; -; Genomic_DNA.
DR   EMBL; BC007656; AAH07656.1; -; mRNA.
DR   EMBL; BC016292; AAH16292.1; -; mRNA.
DR   EMBL; BC050736; AAH50736.1; -; mRNA.
DR   EMBL; BI858659; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BM556795; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BU844974; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS13370.1; -. [O00762-1]
DR   CCDS; CCDS13371.1; -. [O00762-4]
DR   CCDS; CCDS13372.1; -. [O00762-3]
DR   CCDS; CCDS13374.1; -. [O00762-2]
DR   RefSeq; NP_001268670.1; NM_001281741.1.
DR   RefSeq; NP_001268671.1; NM_001281742.1.
DR   RefSeq; NP_008950.1; NM_007019.3. [O00762-1]
DR   RefSeq; NP_861515.1; NM_181799.2. [O00762-4]
DR   RefSeq; NP_861516.1; NM_181800.2. [O00762-3]
DR   RefSeq; NP_861517.1; NM_181801.3. [O00762-2]
DR   UniGene; Hs.93002; -.
DR   PDB; 1I7K; X-ray; 1.95 A; A/B=1-179.
DR   PDB; 4YII; X-ray; 1.80 A; U=27-179.
DR   PDB; 5A31; EM; 4.30 A; Q=29-173.
DR   PDB; 5KHR; EM; 6.10 A; Q=1-179.
DR   PDB; 5L9U; EM; 6.40 A; U=1-179.
DR   PDBsum; 1I7K; -.
DR   PDBsum; 4YII; -.
DR   PDBsum; 5A31; -.
DR   PDBsum; 5KHR; -.
DR   PDBsum; 5L9U; -.
DR   ProteinModelPortal; O00762; -.
DR   SMR; O00762; -.
DR   BioGrid; 116249; 65.
DR   DIP; DIP-52725N; -.
DR   IntAct; O00762; 10.
DR   STRING; 9606.ENSP00000348838; -.
DR   iPTMnet; O00762; -.
DR   PhosphoSitePlus; O00762; -.
DR   EPD; O00762; -.
DR   PaxDb; O00762; -.
DR   PeptideAtlas; O00762; -.
DR   PRIDE; O00762; -.
DR   TopDownProteomics; O00762-1; -. [O00762-1]
DR   TopDownProteomics; O00762-3; -. [O00762-3]
DR   DNASU; 11065; -.
DR   Ensembl; ENST00000335046; ENSP00000335674; ENSG00000175063. [O00762-4]
DR   Ensembl; ENST00000352551; ENSP00000333975; ENSG00000175063. [O00762-3]
DR   Ensembl; ENST00000356455; ENSP00000348838; ENSG00000175063. [O00762-1]
DR   Ensembl; ENST00000372568; ENSP00000361649; ENSG00000175063. [O00762-2]
DR   GeneID; 11065; -.
DR   KEGG; hsa:11065; -.
DR   UCSC; uc002xpl.5; human. [O00762-1]
DR   CTD; 11065; -.
DR   DisGeNET; 11065; -.
DR   GeneCards; UBE2C; -.
DR   HGNC; HGNC:15937; UBE2C.
DR   HPA; CAB011464; -.
DR   HPA; CAB035990; -.
DR   HPA; HPA034569; -.
DR   HPA; HPA054975; -.
DR   MIM; 605574; gene.
DR   neXtProt; NX_O00762; -.
DR   OpenTargets; ENSG00000175063; -.
DR   PharmGKB; PA38057; -.
DR   eggNOG; KOG0421; Eukaryota.
DR   eggNOG; ENOG4111IGV; LUCA.
DR   GeneTree; ENSGT00760000119350; -.
DR   HOGENOM; HOG000233454; -.
DR   HOVERGEN; HBG063308; -.
DR   InParanoid; O00762; -.
DR   KO; K06688; -.
DR   OMA; ELMQLMM; -.
DR   OrthoDB; EOG091G0M7S; -.
DR   PhylomeDB; O00762; -.
DR   TreeFam; TF101116; -.
DR   BRENDA; 2.3.2.B6; 2681.
DR   Reactome; R-HSA-141430; Inactivation of APC/C via direct inhibition of the APC/C complex.
DR   Reactome; R-HSA-174048; APC/C:Cdc20 mediated degradation of Cyclin B.
DR   Reactome; R-HSA-174084; Autodegradation of Cdh1 by Cdh1:APC/C.
DR   Reactome; R-HSA-174154; APC/C:Cdc20 mediated degradation of Securin.
DR   Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1.
DR   Reactome; R-HSA-174184; Cdc20:Phospho-APC/C mediated degradation of Cyclin A.
DR   Reactome; R-HSA-176407; Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase.
DR   Reactome; R-HSA-176408; Regulation of APC/C activators between G1/S and early anaphase.
DR   Reactome; R-HSA-176409; APC/C:Cdc20 mediated degradation of mitotic proteins.
DR   Reactome; R-HSA-176412; Phosphorylation of the APC/C.
DR   Reactome; R-HSA-179409; APC-Cdc20 mediated degradation of Nek2A.
DR   Reactome; R-HSA-2467813; Separation of Sister Chromatids.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; O00762; -.
DR   SIGNOR; O00762; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UBE2C; human.
DR   EvolutionaryTrace; O00762; -.
DR   GeneWiki; UBE2C; -.
DR   GenomeRNAi; 11065; -.
DR   PRO; PR:O00762; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000175063; -.
DR   CleanEx; HS_UBE2C; -.
DR   ExpressionAtlas; O00762; baseline and differential.
DR   Genevisible; O00762; HS.
DR   GO; GO:0005680; C:anaphase-promoting complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:MGI.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0031145; P:anaphase-promoting complex-dependent catabolic process; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0010458; P:exit from mitosis; IMP:UniProtKB.
DR   GO; GO:0010994; P:free ubiquitin chain polymerization; IDA:UniProtKB.
DR   GO; GO:0051436; P:negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0031536; P:positive regulation of exit from mitosis; IMP:UniProtKB.
DR   GO; GO:1904668; P:positive regulation of ubiquitin protein ligase activity; TAS:UniProtKB.
DR   GO; GO:0051437; P:positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition; TAS:Reactome.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0070979; P:protein K11-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0030071; P:regulation of mitotic metaphase/anaphase transition; IBA:GO_Central.
DR   GO; GO:0051439; P:regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd00195; UBCc; 1.
DR   Gene3D; 3.10.110.10; -; 1.
DR   InterPro; IPR000608; UBQ-conjugat_E2.
DR   InterPro; IPR023313; UBQ-conjugating_AS.
DR   InterPro; IPR016135; UBQ-conjugating_enzyme/RWD.
DR   Pfam; PF00179; UQ_con; 1.
DR   SUPFAM; SSF54495; SSF54495; 1.
DR   PROSITE; PS00183; UBIQUITIN_CONJUGAT_1; 1.
DR   PROSITE; PS50127; UBIQUITIN_CONJUGAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell cycle; Cell division; Complete proteome; Mitosis;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:21406692}.
FT   CHAIN         2    179       Ubiquitin-conjugating enzyme E2 C.
FT                                /FTId=PRO_0000082560.
FT   ACT_SITE    114    114       Glycyl thioester intermediate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     39       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_045647.
FT   VAR_SEQ      44     72       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_045648.
FT   VAR_SEQ      73    140       VYEDLRYKLSLEFPSGYPYNAPTVKFLTPCYHPNVDTQGNI
FT                                CLDILKEKWSALYDVRTILLSIQSLLG -> AVGSIRTSST
FT                                VCLLSGPRETQDSSKPLVWGLGWDMRLLLELTLQLFLQMP
FT                                (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_045649.
FT   VARIANT      25     25       G -> D.
FT                                /FTId=VAR_007694.
FT   MUTAGEN     114    114       C->S: Loss of function; inhibition of
FT                                cyclin-B degradation.
FT                                {ECO:0000269|PubMed:15558010,
FT                                ECO:0000269|PubMed:9122200}.
FT   HELIX        30     45       {ECO:0000244|PDB:4YII}.
FT   STRAND       50     54       {ECO:0000244|PDB:4YII}.
FT   STRAND       61     68       {ECO:0000244|PDB:4YII}.
FT   STRAND       78     84       {ECO:0000244|PDB:4YII}.
FT   TURN         87     91       {ECO:0000244|PDB:4YII}.
FT   STRAND       95    100       {ECO:0000244|PDB:4YII}.
FT   STRAND      111    113       {ECO:0000244|PDB:4YII}.
FT   HELIX       116    118       {ECO:0000244|PDB:4YII}.
FT   TURN        119    121       {ECO:0000244|PDB:4YII}.
FT   HELIX       128    140       {ECO:0000244|PDB:4YII}.
FT   HELIX       150    155       {ECO:0000244|PDB:4YII}.
FT   HELIX       159    172       {ECO:0000244|PDB:4YII}.
SQ   SEQUENCE   179 AA;  19652 MW;  0B6F58A1F0665D9A CRC64;
     MASQNRDPAA TSVAAARKGA EPSGGAARGP VGKRLQQELM TLMMSGDKGI SAFPESDNLF
     KWVGTIHGAA GTVYEDLRYK LSLEFPSGYP YNAPTVKFLT PCYHPNVDTQ GNICLDILKE
     KWSALYDVRT ILLSIQSLLG EPNIDSPLNT HAAELWKNPT AFKKYLQETY SKQVTSQEP
//
